Marisa Wexler, MS, senior science writer —

Marisa holds a Master of Science in cellular and molecular pathology from the University of Pittsburgh, where she studied novel genetic drivers of ovarian cancer. Her areas of expertise include cancer biology, immunology, and genetics, and she has worked as a science writing and communications intern for the Genetics Society of America.

Articles by Marisa Wexler

CBD Found to Improve Survival in Worm Models of Parkinson’s

Treatment with cannabidiol (CBD) prevented nerve cell death, extended survival, and reduced toxic protein clumps in nematode worm models of Parkinson’s disease, a new study reports. “These findings supported CBD as an anti-parkinsonian drug,” the researchers wrote, adding that “this CBD neuroprotective action might be due to its antioxidative…

Probiotic Supplements Found to Ease Parkinson’s Constipation in Trial

Probiotic supplements were found to ease multiple measures of constipation in people with Parkinson’s disease in a small clinical trial. According to researchers, the use of such supplements also “significantly” improved quality of life for patients with constipation problems. “In this study, multi-strain probiotics were used to treat [Parkinson’s]…

Dopamine Agonists Linked to Poorer Blood Vessel Function

Rates of blood vessel dysfunction are not significantly different in people with Parkinson’s disease compared to the general population, a small study reports. The findings indicate that, among people with Parkinson’s, smoking and the use of treatments called dopamine agonists are associated with poorer blood vessel function. The…

Alpha-synuclein Clumping Seen to Affect Mitochondria Early

Alpha-synuclein aggregation — the toxic clumping of proteins in nerve cells that is a hallmark of Parkinson’s disease — starts on the membranes of mitochondria, the so-called powerhouse of a cell, according to work in cell models. “Our study provides insights into what is happening in the earliest stages…

Dosing Begins in Phase 2 Study of Experimental Treatment IkT-148009

The first participant has been dosed in a Phase 2 clinical trial testing IkT-148009, an experimental oral therapy for Parkinson’s disease being developed by Inhibikase Therapeutics. This step “represents a major milestone in the development of IkT-148009 for the treatment of Parkinson’s disease and related disorders,” Milton Werner,…

Blood-brain Barrier Signaling Found to Help Regulate Nerve Activity

The activity of a molecular signaling pathway called Delta/Notch in cells of the blood-brain barrier is important for regulating the electrical function of nerve cells, according to a new study using fruit flies. The research, scientists say, could have implications for understanding neurodegenerative diseases like Parkinson’s, which are often…

Your Parkinson’s Community

Woman laying down illustration

Visit the Parkinson’s News Today forums to connect with others in the Parkinson’s community.

View Forums